Clinical Trials Browser

Phase 2 × Recruiting × Plasma cell × Clear all

NCT05272826 2026-03-18

BOREALIS

Phase 2 Recruiting

Multiple Myeloma

NCT06179888 2026-03-18

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04634552 2026-03-17

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT06138275 2026-03-13

Elranatamab in R/R Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT07149857 2026-03-13

CARTITUDE-10

Phase 2 Recruiting

Multiple Myeloma

NCT07266441 2026-03-13

TRIlogy-3

Phase 2 Recruiting

Multiple Myeloma

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT07284758 2026-03-12

MOMENTUM

Phase 2 Recruiting

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

Phase 2 Recruiting

Multiple Myeloma

NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Phase 2 Recruiting

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

NCT06083922 2026-03-06

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Phase 2 Recruiting

Multiple Myeloma

NCT07454382 2026-03-06

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT05091372 2026-03-05

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT03297606 2026-03-04

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06066346 2026-03-04

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Phase 2 Recruiting

Multiple Myeloma

NCT06523621 2026-03-04

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Phase 2 Recruiting

Multiple Myeloma

NCT06103838 2026-02-27

18F-Fluciclovine PET/CT in Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT05344833 2026-02-23

HEME-18

Phase 2 Recruiting

Multiple Myeloma

NCT05530421 2026-02-23

SELVEDge

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05972135 2026-02-23

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma

NCT06100237 2026-02-23

REVIVE

Phase 2 Recruiting

Multiple Myeloma

NCT06711705 2026-02-20

Elranatamab in Relapsed/Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT06207799 2026-02-19

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06500884 2026-02-13

Talisman

Phase 2 Recruiting

Multiple Myeloma

NCT06297226 2026-02-10

QUINTESSENTIAL

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05847569 2026-02-03

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

Multiple Myeloma

NCT04240054 2026-01-28

VICD

Phase 2 Recruiting

Multiple Myeloma, Renal Insufficiency

NCT06974786 2026-01-23

FASTER

Phase 2 Recruiting

Multiple Myeloma

NCT06140524 2026-01-22

LINKER-MGUS1

Phase 2 Recruiting

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT06483100 2026-01-20

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Phase 2 Recruiting

Multiple Myeloma

NCT05922501 2026-01-14

ISABELA

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05898646 2026-01-13

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Phase 2 Recruiting

Immunoglobulin Light-chain Amyloidosis

NCT05231629 2026-01-09

MASTER-2

Phase 2 Recruiting

Multiple Myeloma

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05695508 2025-12-24

HD10/DSMMXX

Phase 2 Recruiting

Multiple Myeloma

NCT05789303 2025-12-22

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT07285044 2025-12-22

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Phase 2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidPlasma cellThoracic

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT06827860 2025-12-18

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04268199 2025-12-15

EASE

Phase 2 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04561492 2025-12-08

PentiMyelo

Phase 2 Recruiting

Multiple Myeloma

NCT06920251 2025-12-03

OPTIMUS-EL

Phase 2 Recruiting

Multiple Myeloma

NCT06947083 2025-12-03

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Phase 2 Recruiting

Neoplasms, Plasma Cell

NCT06517017 2025-11-28

UltraFrailMM

Phase 2 Recruiting

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT07188090 2025-11-28

HSCT

Phase 2 Recruiting

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07110844 2025-11-19

Teclistamab-Daratumumab in AL Amyloidosis

Phase 2 Recruiting

Immunoglobulin Light-chain Amyloidosis

NCT06421675 2025-11-14

EMBRACE

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma, Recurrence